Date: August 14, 2026

Financial Results (Standalone & Consolidated)

Q1 FY27 Performance (in ₹ Crore):

  • Total Revenue: 260.8 (Q4 FY26: 252.1, Q1 FY26: 226.9)
  • EBITDA: 47.2 (Q4 FY26: 44.7, Q1 FY26: 33.2)
  • EBITDA Margin %: 18.09% (Q4 FY26: 17.74%, Q1 FY26: 14.60%)
  • Profit before Tax: 30.1 (Q4 FY26: 27.6, Q1 FY26: 16.3)
  • PBT Margins %: 11.56% (Q4 FY26: 10.96%, Q1 FY26: 7.1%)
  • Tax: 8.2 (Q4 FY26: 7.1, Q1 FY26: 4.2)
  • Profit After Tax: 22.0 (Q4 FY26: 20.6, Q1 FY26: 12.1)
  • PAT Margin %: 8.44% (Q4 FY26: 8.16%, Q1 FY26: 5.30%)

Annual Comparison:

  • FY26 Total Revenue: 940.5 (FY25: 819.8)
  • FY26 EBITDA: 152.9 (FY25: 138.6)
  • FY26 EBITDA Margin %: 16.26% (FY25: 16.91%)
  • FY26 Profit before Tax: 85.5 (FY25: 94.4)
  • FY26 PBT Margins %: 9.09% (FY25: 11.52%)
  • FY26 Tax: 22.3 (FY25: 24.5)
  • FY26 Profit After Tax: 63.2 (FY25: 69.9)
  • FY26 PAT Margin %: 6.72% (FY25: 8.53%)

Manufacturing & Capacity Expansion

Indore Facility Update:

  • Advanced lyophilized injectable facility commenced production in October 2024
  • Designed for WHO GMP, EU GMP, ANVISA, MHRA, and USFDA standards
  • Monthly capacities: Lyophilized vials - 5 million, Liquid vials - 6 million, Ampoules - 10 million
  • Qualification phase completed with all IQ/OQ/PQ and media fills finished
  • Depot and microsphere suite nearing completion
  • Spray-dried route for lipid-based antifungal under setup
  • Annual capacity: Lyophilized Inj - 60 million vials, Liquid Inj (Ampoules) - 120 million, Liquid Inj (Vials) - 72 million units

Regulatory Status:

  • 203 State FDA approvals received to date
  • EU audit completed, certification awaited
  • US FDA filing submitted on behalf of a client

Business Segment Updates

I. Hospital Injectable Platform:

  • Launched AWABAC (monobactam and beta-lactamase inhibitor combination)
  • Focus on advanced gram-positive, gram-negative and antifungal classes
  • Dual-chamber bag technology for anti-infectives (first in India)

II. Women's Health Platform:

  • Ferticare Cluster: Guficin Alpha maintains market leadership in reproductive immunology
  • Puregraf group secured entry into major corporate IVF chains
  • Zenova: Shifting from injectables to prescription-led chronic therapies
  • Pipeline includes chondroprotective agent and metabolic-ovarian segment products

III. Aesthetics & Neurocare:

  • Aesthaderm: Number two in India in botulinum toxin type A
  • Dermal filler and biostimulator portfolio launch planned during FY27
  • Neurocare: Largest therapeutic toxin team in India covering post-stroke spasticity, cerebral palsy, dystonia

IV. Nutra, Ayurveda & Others:

  • Sallaki range regained growth momentum
  • VonpHa (potassium-competitive acid blocker) expanding in GI market
  • NaproPure range (NSAID) preparation for Q2 launch

International Business

Strategic Shift:

  • Moving from distributor-led model to IP-owned, complex-injectable-led market access
  • Gufic Ireland holds Company's first Marketing Authorisation in EU
  • Q1 FY27 approvals across 8 countries: Armenia, Syria, Morocco, South Africa, Bosnia & Herzegovina, Chad, Malaysia, Uganda
  • Therapy basket approvals covering multiple presentations

Key Products with Regulated Market Readiness:

  • 8 molecules with stringent country-ready dossiers
  • Total market size: $824.1 million across select countries
  • Market share goal: 5-10% in identified geographies

R&D Focus

Peptides & Critical API Self-Reliance:

  • Building in-house peptide API development capability
  • Reducing dependence on Chinese API supply chains
  • Focus on GnRH agonist depots, somatostatin analogues, and GnRH agonist microspheres

Novel Drug Delivery Systems:

  • Dual Chamber IV Bags: Commercially launched
  • Dual Chamber Syringes: Multiple products in development pipeline
  • Depot Injection (Microspheres): Multiple products in pipeline including D2/D3 partial agonist LAI, GnRH agonist depot
  • Liposomal Formulation: Lipid-complex polyene antifungal - US/EU block deal signed

API Development:

  • Antifungals: Amphotericin B, Caspofungin, Voriconazole
  • Anticoagulants: LMWH, unfractionated heparin, synthetic Xa inhibitor
  • Tetracycline-class antibiotic API
  • Progestins API for Ferticare franchise

Clinical Programs:

  • 5 ongoing clinical trials: Reproductive immunology, Botulinum Toxin, Gonadotropin, Wound healing, Phase III biosimilar (rFSH)
  • 12 pipeline clinical studies: NDDS formats, women's health adjacencies, antifungal pipeline, CNS long-acting injectables, antiviral

Selvax (Australia) Investment

  • Gufic holds India and partial European rights to Selvax's SVX programme
  • Total holding: 1,685,350 shares
  • Recent investment: USD 50,000 tranche for 378,350 shares at AUD 0.20
  • SVX-2001 (Canine antibody): Phase I in dogs showed 68.4% clinical benefit rate
  • SVX-3001 (Humanized anti-CD40 agonist): Advanced cell-line development, IP filed

Historical Financial Performance

Income Statement (₹ Crore):

| FY | Total Income | EBITDA | EBITDA % | PBT | PBT % | PAT | PAT % |

| FY26 | 943.1 | 152.9 | 16.21% | 85.5 | 9.06% | 63.1 | 6.69% |

| FY25 | 823.4 | 138.6 | 16.83% | 94.4 | 11.46% | 69.9 | 8.49% |

| FY24 | 808.8 | 149.5 | 18.48% | 115.7 | 14.31% | 86.2 | 10.66% |

| FY23 | 693.2 | 137.2 | 19.79% | 106.7 | 15.39% | 79.7 | 11.50% |

| FY22 | 782.3 | 151.1 | 19.31% | 126.8 | 16.21% | 95.8 | 12.25% |

Balance Sheet Highlights (₹ Crore as of Mar-26):

  • Total Equity: 664.2
  • Total Non-Current Liabilities: 159.6
  • Total Current Liabilities: 517.76
  • Total Assets: 1341.6
  • Property, plant and equipment: 467.1
  • Inventories: 324.5
  • Trade Receivables: 297.4
  • Cash and cash equivalent: 60.3

Manufacturing Infrastructure

Unit I at Navsari:

  • Lyophilized: 18 million vials p.a.
  • Ampoule: 12 million p.a.
  • Ointment: 6 million tubes p.a.
  • Lotion: 6 million bottles p.a.
  • Syrup: 6 million bottles p.a.
  • PFS: 2.8 million PFS p.a.

Unit II at Navsari:

  • Lyophilized: 30 million vials p.a.
  • PFS: 30 million PFS p.a.
  • Natural Products: 60 million capsules p.a., 3.6 million powder p.a.

Unit III at Indore:

  • Lyophilized Inj: 60 million vials p.a.
  • Liquid Inj (Ampoules): 120 million p.a.
  • Liquid Inj (Vials): 72 million units p.a.
  • Penem Block: Lyophilized - 3 million vials p.a., Dual Chamber Bags - 2.4 million IV bags, Dry Powder Inj - 30 million vials

Market Presence

Domestic Reach:

  • Products: 100+
  • SKU's: 200+
  • Prescribers: 30,000+
  • Retail Reach: 110,000+
  • Doctors Reach: 120,000+
  • Hospital Coverage: 80% of tertiary care, government institutions

International Presence:

Covering Canada, Costa Rica, Panama, Colombia, Chile, European countries, MENA region, Africa, Australia, and various Asian countries

Corporate Governance

Company Secretary & Compliance Officer: Ami Shah, Membership No. A39579

Investor Relations Contact: Mr. Avik Das, avik.das@guficbio.com, Tel: +91 22 67261000